AstraZeneca: over 40 presentations at upcoming ESMO.
(CercleFinance.com) - AstraZeneca plans to make over 40 presentations at the upcoming ESMO 2017 congress, including data from two pivotal trials in lung cancer.
The drugmaker will detail results from a phase III trial showing statistically-significant progression-free survival benefit with Imfinzi (durvalumab) in patients with stage III unresectable non-small cell lung cancer following standard chemoradiation therapy.
AstraZeneca will also unveil the results of a phase III trial showing statistically-significant progression-free survival with Tagrisso (osimertinib) over current standard-of-care as first-line treatment in previously-untreated patients with locally-advanced or metastatic epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer.
The European Society for Medical Oncology congress will be held in Madrid from 8 to 12 September.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The drugmaker will detail results from a phase III trial showing statistically-significant progression-free survival benefit with Imfinzi (durvalumab) in patients with stage III unresectable non-small cell lung cancer following standard chemoradiation therapy.
AstraZeneca will also unveil the results of a phase III trial showing statistically-significant progression-free survival with Tagrisso (osimertinib) over current standard-of-care as first-line treatment in previously-untreated patients with locally-advanced or metastatic epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer.
The European Society for Medical Oncology congress will be held in Madrid from 8 to 12 September.
Copyright (c) 2017 CercleFinance.com. All rights reserved.